Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2023-11-01 AGM Information
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Egetis’ Nomination Committee for the 2024 Annual General Meeting
AGM Information Classification · 98% confidence The document explicitly discusses the 'Nomination Committee for the 2024 Annual General Meeting (AGM)' and details its composition and assignment regarding proposals for the AGM. This content is directly related to the governance and preparation for the Annual General Meeting. While it is an announcement, the core subject matter is the AGM structure and related nominations, which aligns best with 'AGM Information' (AGM-R). It is not a proxy statement (PSI), a management change announcement (MANG), or a general regulatory filing (RNS), as the topic is highly specific to the AGM's preparatory committee.
2023-11-01 English
Ändring av antalet aktier och röster i Egetis Therapeutics
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement dated October 31, 2023, titled "Ändring av antalet aktier och röster i Egetis Therapeutics" (Change in the number of shares and votes in Egetis Therapeutics). It explicitly states that the total number of shares and votes has increased following a directed share issue announced on October 10, 2023. This directly relates to changes in the company's capital structure and share count. This fits the definition of 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the core content is the notification of the resulting change in the total number of shares and capital due to a prior financing event, SHA is the most precise fit, as it covers changes in share capital/issues. The document is short and appears to be a regulatory disclosure of a capital change event.
2023-10-31 Swedish
Change in the number of shares and votes in Egetis Therapeutics
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces a 'Change in the number of shares and votes in Egetis Therapeutics' due to a private placement, detailing the increase in the total number of shares and the corresponding increase in share capital. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). Although it is a short announcement, the core content is the capital change itself, not just an announcement of a report, making SHA more specific than RPA or RNS.
2023-10-31 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding, stating the 'Reason for major shareholding notification New share issue' and providing 'Before the transaction' and 'After the transaction' figures, including the new percentage (5.82%) and quantity of shares (17,017,220). This structure perfectly matches the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing thresholds. The corresponding code is MRQ.
2023-10-12 English
Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm
Report Publication Announcement Classification · 99% confidence The document is a press release announcing that a prospectus has been prepared, approved, and registered by the SFSA, related to a private placement and subsequent admission to trading of shares on Nasdaq Stockholm. The key phrases are 'Egetis Therapeutics publishes prospectus' and the document structure is that of a formal announcement, not the prospectus itself. Since it announces the publication/availability of a formal document (a prospectus related to financing/capital structure), and the document length is relatively short (4332 chars), it fits the description of a Report Publication Announcement (RPA) or potentially a general Regulatory Filing (RNS). Given the specific nature of announcing the publication of a prospectus related to a private placement (a financing activity), RPA is the most precise fit, as it signals the release of a formal document. If the document *was* the prospectus, it would likely be classified under CAP (Capital/Financing Update), but here it is the *announcement* of the prospectus publication.
2023-10-11 English
Egetis Therapeutics offentliggör prospekt för upptagande till handel av aktier, i den riktade emissionen, på Nasdaq Stockholm
Capital/Financing Update Classification · 98% confidence The document is a press release from Egetis Therapeutics dated October 11, 2023. The headline explicitly states that the company is 'publicly announcing a prospectus for the admission to trading of shares, in the directed issue, on Nasdaq Stockholm' ('Egetis Therapeutics offentliggör prospekt för upptagande till handel av aktier, i den riktade emissionen, på Nasdaq Stockholm'). It mentions that the prospectus, created due to the Directed New Issue (a financing activity), has been approved by the Swedish Financial Supervisory Authority and is available on the company's website. The document is short (4233 characters) and primarily serves to announce the publication of the prospectus related to a capital raise (Directed New Issue). This fits the definition of a Report Publication Announcement (RPA) because it announces the availability of a formal document (the prospectus) rather than being the prospectus itself or a comprehensive financial report. While it relates to capital raising (CAP), the immediate action described is the publication of the associated document.
2023-10-11 Swedish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.